Hughes Financial Services’s BioMarin Pharmaceuticals BMRN Stock Holding History

Hughes Financial Services’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$858	Buy	15 +8	+114%	+$438	﹤0.01%	957
2026 Q1	$395	Buy	7 +2	+40%	+$117	﹤0.01%	975
2025 Q4	$297	Sell	5 -4	-44%	-$218	﹤0.01%	967
2025 Q3	$474	Hold	9	–	–	﹤0.01%	973
2025 Q2	$546	Sell	9 -5	-36%	-$294	﹤0.01%	920
2025 Q1	$951	Buy	+14	New	+$942	﹤0.01%	718

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Hughes Financial Services's BMRN Position: Q2 2026 in Review

Hughes Financial Services increased its BioMarin Pharmaceuticals (BMRN) stake by 114% in Q2 2026, buying an estimated $438 and bringing the position to 15 shares worth $858. The position accounts for ﹤0.01% of the portfolio, ranked #957.

Hughes Financial Services first reported a position in BMRN in Q1 2025 and has held it in 6 quarters since. The position peaked at $951 in Q1 2025. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Hughes Financial Services held 15 shares of BioMarin Pharmaceuticals worth $858 as of Q2 2026.
Hughes Financial Services bought 8 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $438.
BioMarin Pharmaceuticals made up ﹤0.01% of Hughes Financial Services's portfolio in Q2 2026, its #957 holding.
Hughes Financial Services first reported a position in BioMarin Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
Hughes Financial Services's BioMarin Pharmaceuticals position peaked at $951 in Q1 2025.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Hughes Financial Services's 13F filing for Q2 2026, filed 20 Jul 2026.